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Background: Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Chinese herbal
medicine (CHM) has been used as a complementary therapy for cancer for decades in China. CHM was proved to
be effective in improving the quality of life (QOL) and reducing the toxicity associated with chemotherapy in
patients with NSCLC. The purpose of the present trial is to determine whether CHM (Fuzheng Kang’ai decoction
(FZKA), a CHM formula) combined with gefitinib results in longer progression-free survival with less toxicity than
gefitinib alone.
Methods/Design: This is a randomized, placebo-controlled, double-blind trial. This trial is designed to determine if
CHM (FZKA) combined with gefitinib results in longer progression-free survival with less toxicity than gefitinib alone.
A total of 70 NSCLC patients with EGFR mutations will be randomly assigned to treatment group (gefitinib plus
FZKA granules) or control group (gefitinib plus placebo). The primary endpoint is progression-free survival. Secondary
endpoints are: (1) overall survival; (2) disease control rate; (3) QOL, measured with the questionnaire of Functional
Assessment of Cancer Therapy-lung (FACT-L 4.0) and Lung Cancer Symptom Scale and (4) safety.
Discussion: In previous clinical practice, we found that CHM (FZKA) could improve the therapeutic efficacy of
gefitinib. This study will provide objective evidence to evaluate the efficiency of CHM combined with gefitinib in
NSCLC patients with EGFR mutations, and may provide a novel regimen for patients with NSCLC.
Trial registration: Chinese Clinical Trial Registry (www.chictr.org): ChiCTR-IOR-14005679, registered 17 December 2014.
Keywords: Non-small cell lung cancer, Chinese herbal medicine, Fuzheng Kang’ai decoction, Gefitinib, Randomized
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Lung cancer is the leading cause of cancer-related mor-
tality worldwide [1]. Non-small cell lung cancer
(NSCLC) accounts for 85 to 90% of all cases of lung can-
cer, and platinum-based doublet chemotherapy is the
standard treatment for advanced NSCLC. However,
chemotherapy in patients with metastatic NSCLC has
reached a therapeutic plateau, with a response rate of
less than 35%, and a median overall survival of 6.9 to
11.3 months [2,3].
The discovery of targeted therapy has led to a new era
of individualized treatment in lung cancer; epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) have been a new paradigm of lung cancer treat-
ment. Gefitinib, a special TKI of EGFR, is a representa-
tive of first-generation EGFR-TKIs which compete with
adenosine triphosphate (ATP) in binding to the tyrosine
kinase domain. Gefitinib is especially effective in NSCLC
patients with EGFR mutations, with a response rate of
about 70 to 80% [4-6]. EGFR-activating mutations are
found in the kinase domain of the EGFR gene, and com-
prise mostly of in-frame deletions of exon 19 and L858R
substitution in exon 21 [7-9]. Two randomized phase III
trials from Japan demonstrated that progression-free
survival (PFS) with gefitinib was significantly longer than
platinum-based chemotherapy as a first-line treatment
in patients with advanced NSCLC who carried activating
EGFR mutation [10,11]. Although gefitinib results in
longer PFS compared with chemotherapy, most patients
will eventually develop acquired resistance in 10 to
14 months after treatment [12]. In addition, adverse ef-
fects of gefitinib (such as rash, acne or diarrhea) have
sometimes resulted in discontinuation of treatment [13].
Chinese herbal medicine (CHM) has been used in
China for thousands of years. Some studies have re-
ported that CHM could reduce the occurrence of ad-
verse reactions (such as anaemia and neutropenia)
induced by chemotherapy [14]. It is possible that CHM
could be used as an adjuvant to chemotherapy for the
treatment of NSCLC to improve quality of life (QOL)
and compliance to chemotherapy by reducing incidence
of anaemia and neutropenia [15]. CHM could also re-
duce recurrence rate and prolong overall survival [16].
Fuzheng Kang’ai decoction (FZKA), a 12-herb Chinese
formula, was developed to treat NSCLC based on the
theory of combining disease and syndrome with trad-
itional Chinese medicine, and has been used to treat
NSCLC in Guangdong Provincial Hospital of Traditional
Chinese Medicine for more than 10 years. Our previous
retrospective study demonstrated that treatment with
gefitinib plus CHM (FZKA) prolonged PFS and median
survival time (MST) compared with gefitinib alone in
patients with NSCLC [17]. In this study, we aim to as-




This is a randomized, double-blind, placebo-controlled
trial. The study aims to enroll 70 patients with advanced
NSCLC who carry activating EGFR mutations. Partici-
pants are randomized using a ratio of 1:1 to either the
treatment group (gefitinib plus FZKA granules) or con-
trol group (gefitinib plus placebo). Gefitinib combined
with CHM or placebo will be administered until pro-
gression of the disease, or development of unacceptable
toxicities.
The trial protocol has been approved by the Research
Ethical Committee of Guangdong Provincial Hospital of
Traditional Chinese Medicine (reference: B2014-059-01).
The trial will be conducted in accordance with the
Helsinki Declaration [18] and will be monitored by the trial
agency at Guangdong Provincial Hospital of Traditional
Chinese Medicine.
Recruitment and consent
A total of 70 subjects with advanced NSCLC patients
carrying exon 19 deletions or L858R mutations will be
recruited in Guangdong Provincial Hospital of Trad-
itional Chinese Medicine. All candidates will go through
a standardized interview process and receive more infor-
mation about the study and its treatments. Written con-
sent will be obtained from each patient. The purpose,
procedures, potential risks and benefits of the study will
also be explained thoroughly to the participants. The
participants will be able to withdraw from the study at
any time without consequence. The trial will be exe-
cuted from January 2015 to December 2017, including
the enrollment and follow-up periods (Figure 1).
Inclusion criteria
Participants meeting the following criteria will be
included:
1. with histologically or cytologically confirmed stage
IIIB or IV NSCLC with histologic features of
adenocarcinoma, squamous cell carcinoma or
adenosquamous carcinoma;
2. Aged from 18 to 80-years-old;
3. Harboring activating EGFR mutations (either exon
19 deletion or L858R in exon 21);
4. Eastern Cooperative Oncology Group (ECOG)
performance status score 0 to 2;
5. No previous chemotherapy or biologic or
immunologic therapy;
6. Measurable lesion according to the Response
Evaluation Criteria in Solid Tumors (RECIST);
Figure 1 Study flowchart. FZKA, Fuzheng Kang’ai decoction.
Yang et al. Trials  (2015) 16:146 Page 3 of 67. Adequate organ function;
8. Good compliance and sign a written informed
consent.
Exclusion criteria
Participants meeting one or more of the following criteria
will be excluded:
1. Severe hypersensitivity to gefitinib or any
component of FZKA;
2. Received previous drug therapy that targeted EGFR;
3. Expected life expectancy of less than two months;
4. A history of interstitial lung disease;
5. Any evidence of severe or uncontrolled systemic
disease (for example, unstable or uncompensated
respiratory, cardiac, hepatic or renal disease);
6. Diagnosed with central nervous system metastasis
that has not yet been treated with surgery and/or
radiation;
7. Poorly controlled pleural effusion;
8. Pericardial effusion or ascites necessitating
drainage;
9. Active double cancer;
10.Currently pregnant or breastfeeding.Interventions
Patients in the treatment group will receive gefitinib
(250 mg/day orally) plus FZKA granules (1 package/bid
orally), while those in the control group will receive gefi-
tinib(250 mg/day orally) plus placebo granules (1 pack-
age/bid orally). Gefitinib and FZKA or the placebo will
be administered until progression of the disease, devel-
opment of unacceptable toxicities, or withdrawal of
treatment.
The FZKA granules will consist of Pseudostellaria het-
erophylla (Miq.) Pax ex Pax et Hoffm. (Taizishen) 30 g,
Atractylodes macrocephala Koidz. (Baizhu) 15 g, Astrag-
alus membranaceus (Fisch.) Bge. (Huangqi) 30 g, Olden-
landia diffusa (Willd.) Roxb. (Baihuasheshecao) 30 g,
Solanum nigrum L. (Longkui) 30 g, Salvia chinensis Benth
(Shijianchun) 30 g, Cremastra appendiculata (D. Don)
Makino (Shancigu) 30 g, Coix lachrymal-jobi L. (Yiyiren)
30 g. Akebia quinata (Thunb.) Decne (Bayuezha) 30 g, Ru-
bus parviflolius L. (Shepaole) 30 g. Curcuma kwangsiensis
S.G. Lee et C.F. Liang (Ezhu) 15 g, and Glycyrrhiza uralen-
sis Fisch. (Gancao) 10 g [19].
All of the above herbal medicines will be provided by
Guangdong Kangmei Pharmaceutical Co., Ltd. The
FZKA granules used in the trial will be manufactured by
Yang et al. Trials  (2015) 16:146 Page 4 of 6the Yifang Pharmaceutical Co., Ltd. (Foshan, Guangdong
Province, China) that meets the requirements of Good
Manufacturing Practice (GMP). The matching placebo
will be produced by the same manufacturer as the FZKA
granules and consist of starch with no active ingredients.
The colour will be made identical by adding artificial
pigment, and the taste will be adjusted by adding an
intermediate medicine.
Outcome measures
The primary outcome is PFS, which will be assessed
from the date of randomization to the earliest sign of
disease progression, as determined by computed tomog-
raphy or magnetic resonance imaging according to the
RECIST criteria [20], or death from any cause.
The secondary outcomes are MST, objective response
rate, disease control rate and safety. MST will be assessed
from the date of randomization until 50% of participants
are dead from any cause, with the use of methods that are
similar to those used for the analysis of PFS. Tumor re-
sponse will be assessed every six weeks during the first
year after randomization, and every two months after the
first year, until disease progression. The follow-up time of
both groups is two years after recruitment.
Safety assessments
Participants will be questioned and all adverse events
(AEs) will be recorded during the treatment at each visit,
and all AEs reported will be analyzed. Routine physical
examination, full-blood counts and measurements of
blood biochemicals will be measured until study treat-
ment is discontinued. Safety and tolerability will be
assessed according to National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, version
3.0 [21].
Randomization and blinding
Random assignment will be performed after consent is
obtained by using a computer generated, blocked
random-allocation sequence with a 1:1 ratio. Blinding is
ensured by using a matched placebo granule, identical in
color, size, shape and taste. The quality of the matched
trial supplies, such as contents, solubility and bacteria
contaminations, should be controlled rigorously accord-
ing to the GMP standards, and be tested and verified by
researchers.
This trial is a double-blind trial. The first level is for
the case number corresponding to groups (group A,
group B), and the second level is for the group corre-
sponding to intervention (the test and placebo groups).
The numbers are kept in opaque sealed envelopes. The
double levels of blinding are sealed separately, and given
to the leader and the sponsor of the clinical research.
Emergency letters are sent to each of the centers, savedwith the test drug, and properly preserved until the end
of the trial. Treatment assignments are blinded to the
patients and investigators (including statisticians) until
the entire study is completed.
Sample size calculation
The sample size of this study is based on the validity of
assumptions and past clinical experience. Referring to
the results of the IPASS study, the PFS in patients with
EGFR mutations treated with gefitinib was 9.5 months
[22]. In our previous clinical practice, the PFS was
10.5 ± 1.5 months in patients with EGFR mutations
treated with gefitinib plus FZKA [17]. Using a non-
inferiority test, an inspection level alpha = 0.05 and a
grasp 1-beta = 0.80, the sample size is 28 cases in each
group. The number of patients actually provides less
than 90% power, assuming a withdrawal rate of 20%
(28/(1–0.2) = 35). Therefore, we will recruit a total of
70 patients, with 35 patients in each group.
Statistical analysis
The data will be collected and analyzed according to the
intention-to-treat principle. Standard statistical techniques
will be used to describe characteristics of patients in both
groups. We will compare baseline characteristics in both
groups, and if the groups are not comparable, we will per-
form a secondary analysis, adjusting for differences.
PFS and MST will be analyzed by using the Kaplan-
Meier method, and compared using the log-rank test.
Baseline characteristics will be analyzed using either two-
sample t tests or Wilcoxon rank sum tests for continuous
data, and chi-squared tests or Fisher’s exact tests for cat-
egorical data will be conducted for the purpose of normal-
ity. A significance level of 5% will be used throughout the
analysis. The incidence rates of AEs will be compared with
the use of Fisher’s exact tests. All statistical analysis will be
conducted using the SPSS 17.0 statistical package (IBM,
Beijing, China). Experts of Guangdong Provincial Hospital
of Traditional Chinese Medicine were invited to manage
the statistical analysis.
Discussion
Gefitinib is recognized as a standard first-line treatment
for patients with EGFR mutations. However, NSCLC pa-
tients with EGFR mutations who initially respond to gefi-
tinib usually relapse, and the development of secondary
resistance inevitably leads to treatment failure. The most
common molecular mechanisms of secondary resistance
are threonine-to-methionine amino acid change at pos-
ition 790 (T790M) of the EGFR kinase domain (found in
50% of cases), and MET amplification (found in up to 20%
cases) [23,24]. The toxic effect of gefitinib significantly im-
pacts the QOL in patients with NSCLC, and sometimes
causes discontinuation of treatment.
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more popular all over the world [25]. Traditional Chinese
medicine (TCM) is the most popular complementary ther-
apy for cancer patients in China. Among all categories of
TCM, CHM is the most commonly used, and has been
widely adopted by cancer centers of Asian countries
[26,27]. One study reported that CHM could decrease the
incidence of chemotherapy-induced muscle pain and re-
duce symptom severity [28]. CHM may have synergistic
effects when combined with chemotherapy or radiother-
apy. It is still unknown whether CHM could improve the
effect of TKI and reduce its toxicities.
In our previous retrospective study, we found that
treatment with gefitinib plus CHM (FZKA) prolonged
PFS and MST compared with gefitinib alone in patients
with NSCLC. PFS in patients treated with gefitinib plus
CHM was 13.1 months compared with 11.43 months in
patients treated with gefitinib alone. MST in patients
treated with gefitinib plus CHM was 22.83 months com-
pared with 18.7 months in patients treated with gefitinib
alone. The incidence of rash in NSCLC patients treated
with gefitinib plus CHM (FZKA) was lower than those
treated with gefitinib alone. These findings indicate that
FZKA may have a toxicity reducing and efficacy enhan-
cing effect on gefitinib [17].
As our previous study was a retrospective study, a
well-designed randomized controlled trial is needed to
verify the efficacy of CHM (FZKA) plus gefitinib in pa-
tients with NSCLC. If this trial provides high-quality evi-
dence for the efficacy and safety of CHM plus gefitinib,
it will provide useful clinical information for NSCLC, es-
pecially for reducing the toxicity and improving the effi-
cacy of gefitinib. Moreover, it may also provide evidence
for optimizing and promoting integrated CHM com-
bined with Western medical treatment in NSCLC.
Trial status
Recruitment will commence in January 2015, and the
trial is scheduled to end in December 2017.
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